FVL mutation was detected among 66.6% of pregnant patients, 60% of patients using oral contraceptives or treated with hormone therapy, 56.2% of patients with spontaneous DVT, 55.5% with extended DVT, 66.6% of patients with recurrent DVT, 45.4% of patients with family history of venous thromboembolism, 100 % of patients with resistance to anticoagulants and 50% of patients with long-haul air travel (Table 2). Here, F5 is linked to deep vein thrombosis.